An observational prospective study of switching asthma patients from a fixed-dose combination (FDC) Inhaled Corticosteroids [ICS] / Long-Acting Beta-Agonists [LABA] therapy delivered by pMDI Seretide® Evohaler to ICS/LABA delivered by pMDI Flutiform®

drug protocol number
FLT18-KSA
drug sponsor
Mundipharma
drug study
Flutiform
drug trial site
King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh)
drug status
Ongoing
drug phase